Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 8Phase 3 7Phase 1/2 3Phase 2/3 2

Status

Terminated 5Completed 5Active not recruiting 3Withdrawn 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3

Interventions

pembrolizumab 69Nivolumab 39Cyclophosphamide 35Carboplatin 27Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16Ipilimumab 16fludarabine 15Bevacizumab 15Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Cisplatin 12Azacitidine 12belantamab mafodotin 11Pemetrexed 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × auricularum × Clear all
NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT05392946 2026-04-21

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Mayo Clinic

Phase 1/2 Active not recruiting
49 enrolled
Plasma cell

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Mayo Clinic

Phase 1/2 Active not recruiting
39 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡